New York State Common Retirement Fund Reduces Holdings in Grifols, S.A. (NASDAQ:GRFS)

New York State Common Retirement Fund cut its holdings in Grifols, S.A. (NASDAQ:GRFS - Free Report) by 20.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,629,272 shares of the biotechnology company's stock after selling 429,014 shares during the quarter. New York State Common Retirement Fund owned approximately 0.24% of Grifols worth $12,122,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Whitebox Advisors LLC grew its stake in Grifols by 56.2% in the third quarter. Whitebox Advisors LLC now owns 4,221,483 shares of the biotechnology company's stock worth $37,487,000 after purchasing an additional 1,519,093 shares during the period. JPMorgan Chase & Co. grew its holdings in Grifols by 144.0% in the third quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company's stock worth $17,782,000 after purchasing an additional 1,181,959 shares during the period. Anthracite Investment Company Inc. bought a new position in shares of Grifols during the third quarter valued at approximately $5,457,000. Barclays PLC boosted its position in shares of Grifols by 381.2% in the 3rd quarter. Barclays PLC now owns 592,552 shares of the biotechnology company's stock worth $5,261,000 after purchasing an additional 469,401 shares in the last quarter. Finally, Verition Fund Management LLC bought a new position in Grifols during the 3rd quarter valued at approximately $2,636,000.

Grifols Stock Performance

Shares of NASDAQ:GRFS traded up $0.16 during midday trading on Friday, reaching $8.44. 1,378,833 shares of the company's stock traded hands, compared to its average volume of 901,252. Grifols, S.A. has a one year low of $5.30 and a one year high of $9.96. The stock has a 50 day moving average of $7.38 and a 200 day moving average of $8.09. The company has a market cap of $5.80 billion, a price-to-earnings ratio of 7.21 and a beta of 0.40. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley started coverage on Grifols in a report on Wednesday, February 12th. They set an "overweight" rating for the company.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.